Literature DB >> 19048195

Antiviral strategies.

B Müller1, Hans-Georg Kräusslich.   

Abstract

Viruses are obligatory intracellular parasites, whose replication depends on pathways and functions of the host cell. Consequently, it is difficult to define virus-specific functions as suitable targets for anti-infective therapy. However, significant progress has been made in the past 50 years towards the development of effective and specific antivirals. In particular, human immunodeficiency virus, hepatitis C virus, and hepatitis B virus, which cause chronic infections affecting millions of individuals world-wide, are a major focus of antiviral research. Initially, antivirals were mainly directed against virus-specific enzymes; more recently, drugs inhibiting the steps of virus entry or release have been developed. Rational approaches towards drug development, based on information about structure and function of viral proteins and molecular mechanisms of virus-host interactions, have become increasingly successful. Novel strategies currently explored in basic research or preclinical studies include approaches targeting host factors important for virus replication, the exploitation of the innate immune response system as well as the use of gene silencing strategies aimed at interfering with viral gene expression. Today, a number of effective virostatics targeting various viral replication steps are approved for treatment of important viral diseases. However, the use of these drugs is limited by the rapid development of antiviral resistance, which represents a central problem of current antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19048195      PMCID: PMC7120301          DOI: 10.1007/978-3-540-79086-0_1

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  72 in total

Review 1.  Ribavirin--current status of a broad spectrum antiviral agent.

Authors:  N J Snell
Journal:  Expert Opin Pharmacother       Date:  2001-08       Impact factor: 3.889

Review 2.  Viral entry.

Authors:  S B Sieczkarski; G R Whittaker
Journal:  Curr Top Microbiol Immunol       Date:  2005       Impact factor: 4.291

Review 3.  HIV-1 assembly and budding as targets for drug discovery.

Authors:  Feng Li; Carl Wild
Journal:  Curr Opin Investig Drugs       Date:  2005-02

4.  Essential function in vivo for Dicer-2 in host defense against RNA viruses in drosophila.

Authors:  Delphine Galiana-Arnoux; Catherine Dostert; Anette Schneemann; Jules A Hoffmann; Jean-Luc Imler
Journal:  Nat Immunol       Date:  2006-03-23       Impact factor: 25.606

5.  CARD games between virus and host get a new player.

Authors:  Cynthia L Johnson; Michael Gale
Journal:  Trends Immunol       Date:  2005-11-23       Impact factor: 16.687

Review 6.  HIV-1 coreceptors and their inhibitors.

Authors:  N Ray; R W Doms
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

7.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.

Authors:  Annemarie M J Wensing; David A van de Vijver; Gioacchino Angarano; Birgitta Asjö; Claudia Balotta; Enzo Boeri; Ricardo Camacho; Maire-Laure Chaix; Dominique Costagliola; Andrea De Luca; Inge Derdelinckx; Zehava Grossman; Osamah Hamouda; Angelos Hatzakis; Robert Hemmer; Andy Hoepelman; Andrzej Horban; Klaus Korn; Claudia Kücherer; Thomas Leitner; Clive Loveday; Eilidh MacRae; Irina Maljkovic; Carmen de Mendoza; Laurence Meyer; Claus Nielsen; Eline L Op de Coul; Vidar Ormaasen; Dimitris Paraskevis; Luc Perrin; Elisabeth Puchhammer-Stöckl; Lidia Ruiz; Mika Salminen; Jean-Claude Schmit; Francois Schneider; Rob Schuurman; Vincent Soriano; Grzegorz Stanczak; Maja Stanojevic; Anne-Mieke Vandamme; Kristel Van Laethem; Michela Violin; Karin Wilbe; Sabine Yerly; Maurizio Zazzi; Charles A Boucher
Journal:  J Infect Dis       Date:  2005-08-15       Impact factor: 5.226

8.  Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

Authors:  Joerg Petersen; Maura Dandri; Walter Mier; Marc Lütgehetmann; Tassilo Volz; Fritz von Weizsäcker; Uwe Haberkorn; Lutz Fischer; Joerg-Matthias Pollok; Berit Erbes; Stefan Seitz; Stephan Urban
Journal:  Nat Biotechnol       Date:  2008-02-24       Impact factor: 54.908

9.  Identification of host proteins required for HIV infection through a functional genomic screen.

Authors:  Abraham L Brass; Derek M Dykxhoorn; Yair Benita; Nan Yan; Alan Engelman; Ramnik J Xavier; Judy Lieberman; Stephen J Elledge
Journal:  Science       Date:  2008-01-10       Impact factor: 47.728

Review 10.  SARS: systematic review of treatment effects.

Authors:  Lauren J Stockman; Richard Bellamy; Paul Garner
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

View more
  13 in total

1.  Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response.

Authors:  Dan Yan; Stefanie A Krumm; Aiming Sun; David A Steinhauer; Ming Luo; Martin L Moore; Richard K Plemper
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

2.  Identification of 23-(s)-2-amino-3-phenylpropanoyl-silybin as an antiviral agent for influenza A virus infection in vitro and in vivo.

Authors:  Jian-Ping Dai; Li-Qi Wu; Rui Li; Xiang-Feng Zhao; Qian-Ying Wan; Xiao-Xuan Chen; Wei-Zhong Li; Ge-Fei Wang; Kang-Sheng Li
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

3.  S2DV: converting SMILES to a drug vector for predicting the activity of anti-HBV small molecules.

Authors:  Jinsong Shao; Qineng Gong; Zeyu Yin; Wenjie Pan; Sanjeevi Pandiyan; Li Wang
Journal:  Brief Bioinform       Date:  2022-03-10       Impact factor: 11.622

4.  A Bioinformatic Pipeline for Monitoring of the Mutational Stability of Viral Drug Targets with Deep-Sequencing Technology.

Authors:  Yuri Kravatsky; Vladimir Chechetkin; Daria Fedoseeva; Maria Gorbacheva; Galina Kravatskaya; Olga Kretova; Nickolai Tchurikov
Journal:  Viruses       Date:  2017-11-23       Impact factor: 5.048

5.  Advances in Antiviral Material Development.

Authors:  Lili Liang; Ashiq Ahamed; Liya Ge; Xiaoxu Fu; Grzegorz Lisak
Journal:  Chempluschem       Date:  2020-08-21       Impact factor: 3.210

Review 6.  Impact of pharmacological agents on mitochondrial function: a growing opportunity?

Authors:  Megan L Stoker; Emma Newport; James C Hulit; A Phillip West; Karl J Morten
Journal:  Biochem Soc Trans       Date:  2019-12-20       Impact factor: 5.407

7.  A drug screening method based on the autophagy pathway and studies of the mechanism of evodiamine against influenza A virus.

Authors:  Jian-Ping Dai; Wei-Zhong Li; Xiang-Feng Zhao; Ge-Fei Wang; Jia-Cai Yang; Lin Zhang; Xiao-Xuan Chen; Yan-Xuan Xu; Kang-Sheng Li
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

8.  Drug screening for autophagy inhibitors based on the dissociation of Beclin1-Bcl2 complex using BiFC technique and mechanism of eugenol on anti-influenza A virus activity.

Authors:  Jian-Ping Dai; Xiang-Feng Zhao; Jun Zeng; Qian-Ying Wan; Jia-Cai Yang; Wei-Zhong Li; Xiao-Xuan Chen; Ge-Fei Wang; Kang-Sheng Li
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

9.  AVCpred: an integrated web server for prediction and design of antiviral compounds.

Authors:  Abid Qureshi; Gazaldeep Kaur; Manoj Kumar
Journal:  Chem Biol Drug Des       Date:  2016-09-09       Impact factor: 2.817

Review 10.  Bioactive Natural Antivirals: An Updated Review of the Available Plants and Isolated Molecules.

Authors:  Syam Mohan; Manal Mohamed Elhassan Taha; Hafiz A Makeen; Hassan A Alhazmi; Mohammed Al Bratty; Shahnaz Sultana; Waquar Ahsan; Asim Najmi; Asaad Khalid
Journal:  Molecules       Date:  2020-10-22       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.